Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The goal of this interventional study is to determine the strength of cobolimab and dostarlimab that is most tolerated in children and young adults who have advanced solid tumors. This study also aims: (a) to check if it is safe to use cobolimab and dostarlimab combination in children and young adults, (b) to see how to manage the side effects that may occur, and (c) the effect of this treatment in participants
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Participants are eligible to be included in the study only if all of the following criteria apply:
Part 1: Participants with advanced or metastatic solid tumors who have had disease progression after treatment with available therapies that are known to confer clinical benefit and who have limited available treatment options as determined by the investigator. Additionally, exposure to prior immunotherapy or experimental therapies is acceptable:
Part 2:
Participants with Melanoma who have not received prior systemic therapy:
Relapsed/refractory Hodgkin lymphoma (HL) that has failed at least 2 prior lines of systemic therapy)
Exclusion criteria
Participants are excluded from the study if any of the following criteria apply:
Medical conditions:
Prior/ Concomitant therapy:
Prior/Concurrent clinical study experience
Primary purpose
Allocation
Interventional model
Masking
95 participants in 2 patient groups
Loading...
Central trial contact
EU GSK Clinical Trials Call Center; US GSK Clinical Trials Call Center
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal